Sign In
Buy SFT
$0.170
+0 (+0%)
At Close: Jan 17, 2024
Energy Transfer's Most Important Strategic Shift Could Reshape Its Future
07:05am, Thursday, 05'th Mar 2026
Energy Transfer's record-breaking year just revealed a strategic pivot few investors fully appreciate. One major decision could reshape the company's long-term growth trajectory. The yield looks incre
How A Strategy Shift Sparked A Sell-Off In MARA Stock
11:21am, Wednesday, 04'th Mar 2026
MARA Holdings (MARA), a leading Bitcoin mining operator, experienced a notable, high-volume drop of 8.4% on March 3, 2026. This decline followed a considerable fourth-quarter earnings miss reported da
Top EV and Self-Driving Stocks for the Next Mobility Shift
10:06am, Wednesday, 04'th Mar 2026
From charging infrastructure to robotaxis to lithium supply, Beam Global, WeRide and Albemarle offer distinct ways to play the EV and AV trends.
Core Scientific's $10 Billion AI Shift Unlocks Triple-Digit Upside
09:42am, Wednesday, 04'th Mar 2026
Core Scientific's NASDAQ: CORZ stock price struggles with traction in early 2026, but don't be fooled. The company's strategic shift from Bitcoin mining to AI mining is gaining traction and accelerati
BrandPilot AI Launches SearchIQ(TM), Targeting the Rapid Shift Toward AI-Driven Search
08:43am, Tuesday, 03'rd Mar 2026
New AI Search Intelligence Capability Enables Brands to Measure and Optimize Visibility Across Generative AI Platforms Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - BrandPilot AI Inc. (CSE: BPA
Shift4 Is A No-Brainer Buy
08:30am, Tuesday, 03'rd Mar 2026
In light of its Q4 2025 report, Shift4's stock has dropped into the $40s, down ~25% year-to-date. While organic growth is slowing down [expected to decelerate into the teens in 2026], the AI fears are
Shift4 Completes Previously Announced Acquisition of Worldline's North American Subsidiaries
04:30pm, Monday, 02'nd Mar 2026
CENTER VALLEY, Pa.--(BUSINESS WIRE)---- $FOUR--Shift4 (NYSE: FOUR), the leader in integrated payments and commerce technology, today announced the successful completion of its acquisition of Bambora I
NorthWest Announces Updated Mineral Resource at Kwanika Reflecting Strategic Shift to Higher-Grade Copper-Gold Focus
09:49am, Monday, 02'nd Mar 2026
TORONTO, March 02, 2026 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to announce an updated mineral resource estimate for the Kwanika Cent
AI Adoption Drives Investment Shift Beyond Chipmakers
06:51pm, Thursday, 26'th Feb 2026
Investors are looking beyond semiconductor makers as companies across industries deploy artificial intelligence (AI) to transform their operations and products. Generative AI reached 50% of U.S. house
Mega-Cap Value's Quiet Regime Shift: Why MGV Is Built For 2026's Valuation Reset
01:47pm, Thursday, 26'th Feb 2026
The Vanguard Mega Cap Value Index Fund ETF is rated a Buy, positioned for outperformance into 2026 as market rotation favors value over growth. MGV's diversified, less concentrated portfolio structure
Diamondback Energy: Strategy Shift
11:28am, Thursday, 26'th Feb 2026
Diamondback Energy is shifting from acquisitions to organic growth. FANG maintains industry-leading low costs. Recent acquisitions were strategically aimed at cost reduction (or at least slowing the r
Shift4 Announces Fourth Quarter 2025 Results
07:00am, Thursday, 26'th Feb 2026
CENTER VALLEY, Pa.--(BUSINESS WIRE)---- $FOUR--Shift4 (NYSE: FOUR) has posted its fourth quarter 2025 financial results as part of its Q4 2025 Shareholder Letter, which can be viewed here or by naviga
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
04:01pm, Wednesday, 25'th Feb 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
Super Group Q4 Review: Fantastic Shift Of Strategy (Rating Upgrade)
05:37pm, Tuesday, 24'th Feb 2026
Super Group Limited is upgraded to a Buy after delivering strong revenue growth, margin expansion, and strategic execution. SGHC reported Q4 revenues of $578.3m (up 8% y/y) and full-year adjusted EBIT
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
08:30am, Monday, 23'rd Feb 2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Subm
